NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

Patients should have faster access to newly developed drugs and medicines and the Government is prepared to adopt new ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

The global rise in obesity and type 2 diabetes is fueling an epidemic of MASLD and MASH, now recognized as the leading cause ...

SGH will process cord blood to develop and produce allogeneic chimeric antigen receptor (CAR) T-cells designed for cancer ...

Gilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...

Hyderabad: Biopharma player Biological E (BE) entered into a strategic partnership with Danish vaccine maker Bavarian Nordic ...

The European Medicines Agency (EMA) has approved an additional 2 mL pre-filled pen option for subcutaneous administration of ...

Paul Chaplin, President and CEO of Bavarian Nordic said, "We are pleased to announce our first collaboration to expand global access to our Chikungunya Vaccine and also our first partnership with ...

Healx has dosed the first patient in a Phase II trial assessing its lead pipeline candidate HLX-1502 in patients with neurofibromatosis type 1 (NF1), while the FDA approved SpringWorks Therapeutics’ ...

The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their ...